Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Advanced Soft Tissue Sarcoma Clinical Trial

— TOMAS2  

Official title:

Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03838744
• Other study ID #: ISG-TOMAS 2
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 26, 2020
• Est. completion date: February 2025

Study information

• Verified date: September 2023
• Source: Italian Sarcoma Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II study in patient with advanced Soft Tissue Sarcoma (STS) patients who have already received or are not suitable, for a doxorubicin-based treatment.

Description:

Randomized, open-label, active-controlled, multicenter phase II clinical study. Patients will be randomly assigned in a 1:1 ratio to receive trabectedin 1.1 mg/m2 24-hour intravenous continuous infusion every 3 weeks with olaparib (per os) 150 mg twice a day versus trabectedin 1.5 mg/m2 intravenous 24-hour continuous infusion every 3 weeks until progression or unacceptable toxicity as second- or further-line treatment in a population of STS patients who have already received or are not suitable for a doxorubicin-based treatment.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 126
• Est. completion date: February 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provision of written informed consent prior to any study specific procedures.

• Patients with histologically documented and not surgically resectable or metastatic STS that progressed after first- or further-line treatments for relapsing disease.

• At least one previous line of anthracycline-containing chemotherapy for advanced disease or relapsed/progressed within six months of a previous treatment with an anthracycline-containing chemotherapy in the neo-adjuvant/adjuvant setting.

• Central revision will be mandatory in order to enroll a patient. Central revision will assess both diagnosis and adequacy of tumor specimen (minimum requisite will be a formalin-fixed paraffin-embedded block of either a 16-gauge tru-cut biopsy or a non-necrotic surgical tumor specimen). The patient has to consent BReast CAncer genes 1 and 2 (BRCA1 and BRCA 2) evaluation in the interest of avoiding misleading interpretation of resulting data.

• Measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Patients with an ECOG 2 are eligible if it depends solely on orthopedic problems.

• Estimated life expectancy of at least 16 weeks.

• Age =18 years.

• Left Ventricular Ejection Fraction = 50% and/or above lower institutional limit of normality

• Adequate bone marrow, liver and renal function assessed within 7 days prior to

• Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1

Exclusion Criteria:

• Previous enrolment in the present study

• Participation in another clinical study with an investigational product during the last 4 weeks.

• Previous treatment with trabectedin, olaparib or other Poly Adpribose polymerase 1 (PARP-1) inhibitors or analogue.

• Persistent toxicities (= grade 2 according Common Terminology Criteria for Adverse Events - CTCAE) with the exception of alopecia, caused by previous anticancer therapies.

• Dementia or significantly altered mental status (e.g., psychiatric disorder) that would prevent the understanding or rendering of informed consent and compliance with the requirements of this protocol.

• Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function. In particular for history of cardiac disease: congestive heart failure >New York Hearth Association (NYHA) class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension, unstable spinal cord compression (untreated and unstable for at least 28 days prior to study entry), superior vena cava syndrome, extensive bilateral lung disease.

• Immunocompromised patients, e.g., patients who are known to be serologically positive for Human Immunodeficiency Virus (HIV).

• Active clinically serious infections (> grade 2 CTCAE).

• Active viral hepatitis [Hepatitis B Virus - (HBV) or Hepatitis C Virus (HCV) infection]

• Metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, does not require corticosteroid treatment, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.

• Patients with seizure disorders requiring medication (such as steroids or anti-epileptics).

• Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 28 days before the start of treatment. Pregnancy test will be repeated and confirmed on cycle 1 day 1 before treatment start. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 5 months after last dose of study drug.

• Patients with evidence or history of bleeding diathesis.

• Patients undergoing renal dialysis.

• Patients unable to swallow oral medications.

• Uncontrolled diabetes (fasting glucose > 2 x Upper Normal Limit).

• Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone = 20 mg for adrenal insufficiency). Topical or inhaled corticosteroids are permitted.

• Other malignancy unless curatively treated with no evidence of disease for =5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ , Stage 1, grade 1 endometrial carcinoma. Patients with a history of localised triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease

• Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drugs).

• Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry

• Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed).

• Major surgery within 4 weeks of start of study. Thus, patients must have recovered from wound or directly surgical related complications at time of study randomization.

• Investigational drug therapy outside of this trial during or within 4 weeks of study entry.

• Patients with known hypersensitivity to trabectedin, olaparib or to their excipients.

• Patients can receive a stable dose of bisphosphonates for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment with the study drugs.

• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.

• A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits.

• Resting ElectroCardioGram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, corrected QT prolongation >500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.

• Concomitant use of known strong CYtochromeP3A (CYP3A) inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study drugs is 2 weeks.

• Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study drugs is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.

• Previous allogenic bone marrow transplant or double umbilical cord blood transplantation

• Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of them

Related Conditions & MeSH terms

• Advanced Soft Tissue Sarcoma
• Sarcoma

Intervention

Drug:
• Standard arm: Trabectedin in monotherapy
Trabectedin in monotherapy
• Experimental arm: Trabectedin + Olaparib
Trabectedin given in combination to olaparib

Locations

Country	Name	City	State
Italy	Centro di Riferimento Oncologico di Aviano	Aviano	PD
Italy	Azienda Ospedaliero-Universitaria Di Bologna	Bologna	BO
Italy	Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors	Bologna
Italy	Fondazione del Piemonte per l'Oncologia IRCC Candiolo	Candiolo	Torino
Italy	I.R.S.T. di Meldola	Meldola	FC
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano	MI
Italy	Istituto Europeo di Oncologia	Milano	MI
Italy	Irccs Istituto Oncologico Veneto (Iov)	Padova
Italy	Azienda Ospedaliera Universitaria Paolo Giaccone	Palermo	PA
Italy	Nuovo Ospedale di Prato	Prato	Firenze
Italy	Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I	Roma
Italy	Policlinico Universitario Campus Biomedico	Roma	RM
Italy	Ospedale San Giovanni Bosco	Torino	TO

Sponsors (3)

Lead Sponsor	Collaborator
Italian Sarcoma Group	AstraZeneca, PharmaMar

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. — View Citation

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9. — View Citation

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Erratum In: Lancet Oncol. 2017 Sep;18(9):e510. — View Citation

Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013 Jun;24(6):1703-9. doi: 10.1093/annonc/mds659. Epub 2013 Feb 5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free Survival (PFS)	Survival without disease progression	At 6 months
Secondary	Overall Survival (OS)	Survival from the first dose treatment to death for any cause	At 3 years
Secondary	Overall Survival rate	Proportion of patients who are still alive at 12 months after have started the treatment	At 12 months
Secondary	Progression free Survival (PFS)	Survival without disease progression	At 3 years
Secondary	Progression free Survival Rate	Proportion of patients who did not progress at 6 months after have started the treatment	At 6 months
Secondary	Growth Modulation Index (GMI)	Ratio of time to progression with the nth line of therapy to the those with the n-1th line.	Week 6, week 12, week 18, week 27, week 36
Secondary	Adverse events related to the treatment	Safety in term of adverse event is evaluate from the firs treatment dose throughout the study according to CTCAE 5.0	Week 3, week6, week 9, week 12, week 18, week 27, week 36
Secondary	Quality of Life according the 30 questions European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC Quality of Life Questionnaire C30)	Evaluation of the quality of life collected with EORTC Quality of Life Questionnaire C30	Week 3, week6, week 9, week 12, week 18, week 27, week 36
Secondary	Quality of Life according the questionnaire Euro Quality Of Life 5 Domains (EQ-5D)	Evaluation of the quality of life collected with EQ-5D	Week 3, week6, week 9, week 12, week 18, week 27, week 36
Secondary	Over all Response Rate	Overall response rate according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1	At week 18